Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review.
- 1Department of Pediatric Respiratory Medicine, Guiyang Maternal and Child Health Care Hospital, Guiyang, Guizhou, China.
- 2Department of Critical Care Medicine, Guizhou Third People's Hospital, Guiyang, Guizhou, China.
Abstract
Background
Idiopathic pulmonary hemosiderosis (IPH) is a rare disease characterized by recurrent diffuse alveolar hemorrhage in children. Corticosteroids are the conventional first-line treatment, and immunosuppressive agents also constitute a mainstay of management. However, evidence is derived almost entirely from small observational studies, and no standardized recommendations exist.Methods
We systematically searched PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and Chinese databases (CNKI and Wanfang) from inception to 24 September 2026, with no language restrictions. Studies reporting treatment for IPH in children (0-18 years) were included; a narrative synthesis was performed.Results
A total of 149 studies were included. Corticosteroids were the first-line treatment, with 78.7% of the 494 children with IPH or undetermined etiology in the largest multicenter cohort (n = 567) receiving corticosteroid monotherapy. The overall relapse rate ranged from approximately 35% to 60% across small single-center cohorts, most commonly triggered by respiratory infections and corticosteroid tapering. Immunosuppressive agents, including azathioprine, hydroxychloroquine, cyclophosphamide, leflunomide, and 6-mercaptopurine, were added for refractory, steroid-dependent, or relapsing disease. Biological agents such as rituximab also emerged as promising steroid-sparing options. Adjunctive therapies included intravenous immunoglobulin, ECMO, arterial embolization, and iron chelation. In a single-center IPH cohort of 41 children, mortality was 27.3% (6 of 22 children followed).Conclusions
Corticosteroids remain the cornerstone of pediatric IPH treatment, with immunosuppressive or biologic agents reserved for refractory disease. Given the absence of high-quality evidence, multicenter prospective studies with standardized protocols are urgently needed.Systematic review registration
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261486860, PROSPERO CRD420261486860.
Related
- Case Report: Effective use of rituximab in children with steroid-resistant/dependent idiopathic pulmonary hemosiderosis: description of two cases and literature review
- Perioperative Antifibrotic Treatment and Early Postoperative Outcomes in Patients With Idiopathic Pulmonary Fibrosis Undergoing Lung Cancer Surgery: A Systematic Review and Meta‐Analysis
- Treatment of idiopathic segmental infarction of the greater omentum in children via transumbilical single-port laparoscopy
- A novel inhalable tanshinone IIA lipid nanocrystal formulation for the enhanced treatment of idiopathic pulmonary fibrosis.
- Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.
BibTeX
@article{liu2026treatment,
title = {{Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review.}},
author = {PengCheng Liu and ZhiChao Lei},
journal = {Frontiers in pediatrics},
year = {2026},
month = oct,
doi = {10.3389/fped.2026.1982437},
url = {https://europepmc.org/article/MED/42923410},
note = {CC BY},
}
RIS
TY - JOUR
TI - Treatment of idiopathic pulmonary hemosiderosis in children: a systematic review.
AU - PengCheng Liu
AU - ZhiChao Lei
PY - 2026
DA - 2026/10/08
JO - Frontiers in pediatrics
DO - 10.3389/fped.2026.1982437
UR - https://europepmc.org/article/MED/42923410
AB - Background Idiopathic pulmonary hemosiderosis (IPH) is a rare disease characterized by recurrent diffuse alveolar hemorrhage in children. Corticosteroids are the conventional first-line treatment, and immunosuppressive agents also constitute a mainstay of management. However, evidence is derived almost entirely from small observational studies, and no standardized recommendations exist.Methods We systematically searched PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and Chinese databases (CNKI and Wanfang) from inception to 24 September 2026, with no language restrictions. Studies reporting treatment for IPH in children (0-18 years) were included; a narrative synthesis was performed.Results A total of 149 studies were included. Corticosteroids were the first-line treatment, with 78.7% of the 494 children with IPH or undetermined etiology in the largest multicenter cohort (n = 567) receiving corticosteroid monotherapy. The overall relapse rate ranged from approximately 35% to 60% across small single-center cohorts, most commonly triggered by respiratory infections and corticosteroid tapering. Immunosuppressive agents, including azathioprine, hydroxychloroquine, cyclophosphamide, leflunomide, and 6-mercaptopurine, were added for refractory, steroid-dependent, or relapsing disease. Biological agents such as rituximab also emerged as promising steroid-sparing options. Adjunctive therapies included intravenous immunoglobulin, ECMO, arterial embolization, and iron chelation. In a single-center IPH cohort of 41 children, mortality was 27.3% (6 of 22 children followed).Conclusions Corticosteroids remain the cornerstone of pediatric IPH treatment, with immunosuppressive or biologic agents reserved for refractory disease. Given the absence of high-quality evidence, multicenter prospective studies with standardized protocols are urgently needed.Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261486860, PROSPERO CRD420261486860.
SN - 2296-2360
ER -